Dr. David Sugarbaker

Dr. David J. Sugarbaker, MD
Architect of Trimodal Therapy
Born	August 5, 1953
Died	August 29, 2018 (age 65)
Institution	Brigham and Women's Hospital
Key Innovation	Trimodal Therapy
Program Founded	International Mesothelioma Program (2002)
Survival Achievement	35.3 months median
Free Case Review →

Executive Summary

Dr. David J. Sugarbaker stands among the most influential mesothelioma surgeons in American history. At Brigham and Women's Hospital in Boston, he pioneered the extrapleural pneumonectomy (EPP) procedure, modified existing lung-removal techniques to optimize them for mesothelioma patients, and developed trimodal therapy—the combination of surgery, chemotherapy, and radiation that became the standard approach for operable mesothelioma. His research demonstrated that this aggressive approach could extend median survival to 35.3 months when combined with intraoperative heated chemotherapy, with half of patients living even longer. In 2002, Sugarbaker founded the International Mesothelioma Program (IMP), creating the world's largest mesothelioma research and treatment initiative. By the time of his death in 2018, he was among the most experienced mesothelioma surgeons in history.

The International Mesothelioma Program brought together five major Boston-area medical institutions—Brigham and Women's Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, the Boston VA Healthcare System, and Harvard School of Public Health—creating an unprecedented concentration of mesothelioma expertise. This collaboration enabled large-scale research studies, clinical trials, and training programs that advanced the field worldwide.

Sugarbaker also developed the Brigham staging system for mesothelioma, which helped surgeons identify patients most likely to benefit from aggressive surgical treatment. His work on the "four-gene ratio" diagnostic test opened pathways for personalized treatment planning based on tumor molecular characteristics. The training programs he established have produced a generation of thoracic surgeons who continue his mission of improving outcomes for mesothelioma patients at institutions across the country.

Key Facts

Key Facts: Dr. David Sugarbaker's Contributions

Surgical Innovation: Pioneered extrapleural pneumonectomy (EPP) for mesothelioma Trimodal Therapy: Developed approach combining surgery + chemotherapy + radiation Survival Achievement: 35.3 months median survival with trimodal therapy + HIPEC Program Founded: International Mesothelioma Program at Brigham and Women's Hospital (2002) Collaborating Institutions: Brigham and Women's, Dana-Farber, MGH, Boston VA, Harvard School of Public Health Brigham Staging System: Created staging system identifying surgical candidates Four-Gene Ratio Test: Developed molecular tool for personalized treatment decisions Surgical Volume: Among the most experienced mesothelioma surgeons in history Training Legacy: Trained numerous thoracic surgeons who continue his methods Research Output: Extensive body of publications establishing surgical treatment standards

Who Was Dr. David Sugarbaker and Why Is He Considered a Pioneer?

Dr. David J. Sugarbaker (August 5, 1953 – August 29, 2018) was a thoracic surgeon who dedicated his career to developing surgical treatments for mesothelioma patients who previously had few options. Based at Brigham and Women's Hospital in Boston, Sugarbaker transformed the surgical treatment of this asbestos-related cancer from a largely futile endeavor into a viable therapeutic option for carefully selected patients.

His approach was distinctly aggressive. At a time when many physicians considered mesothelioma surgery pointless, Sugarbaker developed and refined techniques that gave patients fighting chances they otherwise would not have had. His philosophy was that mesothelioma, while challenging, could be controlled in some patients through comprehensive multimodal treatment.

"Dr. Sugarbaker gave mesothelioma patients hope when they had none. His willingness to operate on patients others had written off—combined with his meticulous research tracking outcomes—created the evidence base that surgery could extend lives. Many of our clients are alive today because of the surgical techniques he pioneered."

— Paul Danziger, Founding Partner, Danziger & De Llano

What Was Extrapleural Pneumonectomy and How Did Dr. Sugarbaker Improve It?

Extrapleural pneumonectomy (EPP) is an aggressive surgical procedure that removes the affected lung, the pleura (lining around the lung), the pericardium (lining around the heart), and the diaphragm. The goal is to remove as much cancer as possible, achieving what surgeons call "complete macroscopic resection."

While EPP existed before Sugarbaker, he significantly refined the procedure. In 1992, the Annals of Thoracic Surgery published his research on overcoming the technical difficulties of EPP through improved operative techniques. His modifications included:

• Improved Patient Selection: Developing criteria to identify patients most likely to benefit
• Refined Surgical Technique: Reducing operative mortality and complications
• Reconstruction Methods: Better approaches to rebuilding the diaphragm and pericardium
• Perioperative Care: Protocols to optimize patient outcomes before and after surgery

Structure Removed	Rationale
Affected Lung	Mesothelioma typically encases the lung
Parietal Pleura	Primary site of mesothelioma origin
Visceral Pleura	Disease spreads along pleural surfaces
Pericardium	Often involved with advanced disease
Hemidiaphragm	Frequently invaded by tumor

⚠️ Note on Current Practice: Following the 2011 MARS trial showing that EPP offered no survival benefit in a randomized setting, many centers transitioned to lung-sparing approaches like pleurectomy with decortication (P/D). However, Sugarbaker's research established principles that continue to guide all mesothelioma surgery.

What Is Trimodal Therapy and Why Did Dr. Sugarbaker Develop It?

Sugarbaker's most significant contribution was developing trimodal therapy—the combination of surgery, chemotherapy, and radiation therapy to maximize survival in patients with operable mesothelioma.

The Trimodal Approach

Component	Timing	Purpose
Chemotherapy	Before and/or after surgery	Shrink tumor, kill microscopic disease
Surgery (EPP)	Central component	Remove all visible disease
Radiation	After surgery	Destroy remaining cancer cells

Sugarbaker's research demonstrated that combining these treatments achieved better results than any single modality alone. His studies showed that patients receiving intraoperative heated chemotherapy had significantly longer survival than those who did not.

HIPEC Integration

In select patients, Sugarbaker's team added hyperthermic intraoperative chemotherapy—heated chemotherapy solution (42-43°C) circulated through the chest cavity during surgery. This approach achieved the remarkable median survival of 35.3 months, with half of patients living even longer.

✅ Survival Achievement: Dr. Sugarbaker's trimodal therapy with HIPEC achieved median survival of 35.3 months—nearly three years—for appropriately selected patients. This represented a dramatic improvement over historical survival of 12-18 months with single-modality treatment.

What Was the International Mesothelioma Program?

In 2002, Sugarbaker founded the International Mesothelioma Program (IMP) at Brigham and Women's Hospital, creating the world's largest mesothelioma research and treatment initiative.

Collaborating Institutions

The IMP brought together specialists from five Boston-area institutions:

• Brigham and Women's Hospital – Surgical treatment and inpatient care
• Dana-Farber Cancer Institute – Medical oncology and chemotherapy
• Massachusetts General Hospital – Radiation oncology
• Boston VA Health Care System – Veteran care
• Harvard School of Public Health – Epidemiology and research

This unprecedented multidisciplinary collaboration established Boston as the epicenter of mesothelioma research and set the standard for comprehensive cancer care.

"The International Mesothelioma Program was revolutionary because it recognized that mesothelioma requires expertise across multiple disciplines. Dr. Sugarbaker understood that no single physician or hospital could provide everything these patients need. The collaborative model he created continues to guide how the best cancer centers approach this disease."

— Rod De Llano, Founding Partner, Danziger & De Llano

IMP Contributions

Under Sugarbaker's leadership, the IMP produced numerous advances:

• Tissue Banking: Established protocols that enabled genomic research
• Clinical Trials: Tested innovative therapeutic combinations
• Staging Systems: Developed the Brigham staging system for surgical planning
• Molecular Tools: Created the four-gene ratio test for personalized medicine
• Training Programs: Educated thoracic surgeons who spread these techniques worldwide

What Was the Brigham Staging System?

Dr. Sugarbaker developed the Brigham staging system to identify which patients were appropriate candidates for aggressive surgical intervention.

Stage	Disease Extent	Surgery Appropriate?
Stage I	Disease confined to pleura	Yes – Resectable
Stage II	Resectable with positive lymph nodes	Yes – Resectable
Stage III	Extended locally but technically resectable	Selected cases only
Stage IV	Distant metastases or unresectable	No – Not candidates for EPP

This staging system specifically addressed the question of surgical resectability—helping surgeons determine which patients could benefit from aggressive surgery and which should receive non-surgical treatment.

What Was the Four-Gene Ratio Test?

Sugarbaker's team at the IMP developed the four-gene ratio test, a molecular tool that determines the best mesothelioma treatment options based on a patient's individual genetic characteristics.

This innovation represented an early step toward personalized medicine in mesothelioma care. By analyzing the expression levels of four specific genes in tumor tissue, physicians could better predict:

• How aggressively the cancer might behave
• Which treatments were most likely to be effective
• Whether surgery would likely benefit the patient

The four-gene ratio test demonstrated that not all mesotheliomas are alike and that treatment decisions should be tailored to individual patients.

What Is Dr. Sugarbaker's Legacy?

Dr. David Sugarbaker died on August 29, 2018, at age 65, having transformed mesothelioma treatment from a largely hopeless endeavor into a field where survival could be measured in years rather than months for selected patients.

Immediate Legacy

• Surgical Volume: Among the most experienced mesothelioma surgeons in history
• Training: Educated thoracic surgeons who continue his methods at institutions worldwide
• Research: Published extensively, creating the evidence base for surgical treatment
• Institution Building: The IMP continues operating under Dr. Raphael Bueno's leadership

Lasting Impact

• Multimodal Therapy: The principle of combining treatments remains standard practice
• Personalized Medicine: Molecular testing to guide treatment decisions is now routine
• Surgical Selection: Careful patient selection based on staging continues to guide practice
• Research Infrastructure: Tissue banks and databases support ongoing research

"Dr. Sugarbaker's greatest gift to mesothelioma patients was proving that survival was possible. Before his work, a mesothelioma diagnosis felt like an immediate death sentence. He showed that with the right treatment approach, patients could live for years—years they otherwise would not have had with their families."

— David Foster, Client Advocate, Danziger & De Llano

How Does Dr. Sugarbaker's Work Connect to Other Mesothelioma Researchers?

Dr. Sugarbaker's contributions exist within a broader ecosystem of mesothelioma research:

• Dr. Paul H. Sugarbaker (unrelated): Pioneered HIPEC for peritoneal mesothelioma
• Dr. Robert Cameron: Championed lung-sparing P/D as alternative to EPP
• Dr. Raphael Bueno: Succeeded Sugarbaker at the IMP, advancing genomic research
• Dr. Paul Baas: Led immunotherapy trials that created non-surgical options
• Dr. Irving Selikoff: Established the asbestos-mesothelioma connection that made treatment possible

Get Help Today

If you or a loved one has been diagnosed with mesothelioma, accessing the best possible treatment—including the surgical techniques Dr. Sugarbaker pioneered—can significantly impact survival. You may also be entitled to compensation from the companies responsible for your asbestos exposure.

The experienced mesothelioma attorneys at Danziger & De Llano have helped thousands of families navigate both the medical and legal challenges of this diagnosis.

📞 Call (866) 222-9990 or request a free case review online.

See Also

• History of Mesothelioma Research
• Dr. Raphael Bueno (Successor at IMP)
• Dr. Paul H. Sugarbaker (Peritoneal Mesothelioma Pioneer)
• Dr. Robert Cameron
• Dr. Paul Baas
• Brigham and Women's Hospital
• Treatment Options
• Mesothelioma Treatment Centers